Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab Mechanisms in RRMS
NCT02419378Phase 4Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Jun 2015
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Universitätsklinikum Münster. Started Jun 2015; status: completed.
02
Drugs
alemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02419378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419378.